+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2023-2030- Product Image
Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2023-2030- Product Image
Sale

Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2023-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5264367
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiviral Therapeutics Market size was estimated at USD 69.54 billion in 2022, USD 75.53 billion in 2023, and is expected to grow at a CAGR of 8.32% to reach USD 131.82 billion by 2030.

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics. Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

Regional Insights

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options. The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Limited, AstraZeneca PLC, Atea Pharmaceuticals, Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Ltd., Cocrystal Pharma, Inc., Daiichi Sankyo Company, Ltd., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Labs Limited, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Syngene International Limited, Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Hepatitis Antiviral Drug
    • Herpes Antiviral Drug
    • HIV Antiviral Drug
    • Influenza Antiviral Drug
  • Therapy
    • DNA Polymerase Inhibitors
      • Non-nucleosides
      • Purine Nucleoside Analogues
      • Pyrimidine Nucleoside Analogues
    • Neuraminidase Inhibitors
    • Protease Inhibitors
    • Reverse Transcriptase Inhibitors
      • Nonnucleoside RTIs
      • Nucleoside RTIs
      • Nucleotide RTIs
  • Distribution
    • Hospital Pharmacy
    • Independent Pharmacy & Drug Store
    • Online Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Antiviral Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Antiviral Therapeutics Market?
  4. What is the market share of the leading vendors in the Antiviral Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Antiviral Therapeutics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antiviral Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Viral Diseases Including HIV and Hepatitis
5.1.1.2. Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
5.1.1.3. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
5.1.2. Restraints
5.1.2.1. Relatively High Cost Associated with Antiviral Drug Treatment
5.1.3. Opportunities
5.1.3.1. Advancements in Molecular Biology Promoting Drug Development
5.1.3.2. Improved Testing and Analysis of Viral Infections
5.1.4. Challenges
5.1.4.1. Adverse Effects of Antiviral Drugs
5.2. Market Segmentation Analysis
5.2.1. Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
5.2.2. Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
5.2.3. Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Antiviral Therapeutics Market, by Drug
6.1. Introduction
6.2. Hepatitis Antiviral Drug
6.3. Herpes Antiviral Drug
6.4. HIV Antiviral Drug
6.5. Influenza Antiviral Drug
7. Antiviral Therapeutics Market, by Therapy
7.1. Introduction
7.2. DNA Polymerase Inhibitors
7.3.1. Non-nucleosides
7.3.2. Purine Nucleoside Analogues
7.3.3. Pyrimidine Nucleoside Analogues
7.3. Neuraminidase Inhibitors
7.4. Protease Inhibitors
7.5. Reverse Transcriptase Inhibitors
7.6.1. Nonnucleoside RTIs
7.6.2. Nucleoside RTIs
7.6.3. Nucleotide RTIs
8. Antiviral Therapeutics Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Independent Pharmacy & Drug Store
8.4. Online Pharmacy
9. Americas Antiviral Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antiviral Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antiviral Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
12.3.2. New Product Launch & Enhancement
12.3.2.1. Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
12.3.3. Award, Recognition, & Expansion
12.3.3.1. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Alkem Laboratories Limited
13.1.4. AstraZeneca PLC
13.1.5. Atea Pharmaceuticals, Inc.
13.1.6. Aurobindo Pharma Limited
13.1.7. Bristol-Myers Squibb Company
13.1.8. Cipla Ltd.
13.1.9. Cocrystal Pharma, Inc.
13.1.10. Daiichi Sankyo Company, Ltd.
13.1.11. Dr. Reddy’s Laboratories Ltd.
13.1.12. Eli Lilly and Company
13.1.13. F. Hoffmann-La Roche Ltd
13.1.14. Gilead Sciences, Inc.
13.1.15. GlaxoSmithKline PLC
13.1.16. Hetero Labs Limited
13.1.17. Johnson & Johnson Services Inc.
13.1.18. Merck & Co., Inc.
13.1.19. Novartis AG
13.1.20. Pfizer Inc.
13.1.21. Sanofi S.A.
13.1.22. Sun Pharmaceutical Industries Limited
13.1.23. Syngene International Limited
13.1.24. Takeda Pharmaceutical Company Limited
13.1.25. Themis Medicare Ltd.
13.1.26. Venatorx Pharmaceuticals, Inc.
13.1.27. Viatris Inc.
13.1.28. Zydus Lifesciences Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. ANTIVIRAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. ANTIVIRAL THERAPEUTICS MARKET DYNAMICS
FIGURE 7. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
FIGURE 8. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
FIGURE 10. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
FIGURE 12. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 14. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 22. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 6. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 11. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 13. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 24. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 43. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 44. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 48. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 49. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 70. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 71. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 72. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 75. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 76. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 77. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 85. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 86. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 87. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 116. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 117. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 132. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 136. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 137. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 141. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 142. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 143. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 151. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 152. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 161. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 162. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 176. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 177. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 178. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 181. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 182. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 183. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 187. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 207. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 221. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 222. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 223. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 236. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 237. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 238. ANTIVIRAL THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Atea Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Cocrystal Pharma, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Syngene International Limited
  • Takeda Pharmaceutical Company Limited
  • Themis Medicare Ltd.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMarch 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 75.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 131.82 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 180 Pages
  • Global
From
Global Antiviral Drugs Market Report and Forecast 2023-2031 - Product Image

Global Antiviral Drugs Market Report and Forecast 2023-2031

  • Report
  • 147 Pages
  • Global
From
Global Antiviral Therapeutics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Antiviral Therapeutics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 188 Pages
  • Global
From
Global Antiviral Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Antiviral Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 155 Pages
  • Global
From
Antiviral Combination Therapy Global Market Report 2024 - Product Image

Antiviral Combination Therapy Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From

About the Antivirals Market

The Antivirals market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat viral infections. Antivirals are used to treat a wide range of viral infections, including influenza, HIV, herpes, hepatitis, and other respiratory infections. Antivirals work by targeting the virus itself, preventing it from replicating and spreading throughout the body. They can also be used to reduce the severity of symptoms and shorten the duration of the illness. Antivirals are typically administered orally or intravenously, depending on the type of virus and the severity of the infection. In some cases, antivirals may be used in combination with other drugs to increase their effectiveness. Some of the major companies in the Antivirals market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb. These companies produce a variety of antiviral drugs, including those used to treat influenza, HIV, herpes, and hepatitis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.